Instructed in new medication Temazepam to manage insomnia. In addition, warned of possible S/E such as drowsiness, dizziness, lethargy, disturbed coordination, daytime sedation, confusion, nightmares, vertigo, euphoria, weakness, headache, fatigue, nervousness, anxiety, depression, blurred vision, diarrhea, nausea, dry mouth, physical and psychological dependence. Avoid alcohol during therapy. Caution when performing activities that require mental alertness or physical coordination. Instructed not to discontinue drug abruptly if it is taken for 1 month or longer.
Instructed in new medication Amitriptyline to manage depression. In additon, warned of possible S/E such as coma, seizures, hallucinations, delusions, disorientation, ataxia, tremor, peripheral neuropathy, anxiety, insomnia, restlessness, drowsiness, dizziness, weakness, fatigue, headache, extrapyramidal reactions, MI, stroke, arrhythmias, heart block, orthostatic hypotension, tachycardia, ECG changes, hypertension, edema, blurred vision, tinnitus, mydriasis, increased intraocular pressure, dry mouth, nausea, vomiting, anorexia, epigastric distress, diarrhea, constipation, paralytic ileum, urine retention, agranulocytosis, thrombocytopenia, leukopenia, eosinophilia, hypoglycemia, hyperglycemia, rash, urticaria, photosensitivity, diaphoresis and hypersensitivity reaction. Instructed to take full dose at bedtime but warned patient of possible morning orthostatic hypotension. Avoid alcohol during drug therapy. Consult MD before taking other medications. Avoid activities that require alertness and good psychomotor coordination until CNS effects of drug are known. Drowsiness and dizziness usually subside after a few weeks. Dry mouth may be relieved with sugarless hard candy or gum. Saliva substitutes may be needed. Instructed to use a sun block, wear protective clothing and avoid prolonged exposure to strong sunlight. To prevent photosensitivity reactions. Do not stop drug therapy abruptly.
Instructed in new medication Aspirin to manage rheumatoid arthritis. In addition, warned of possible S/E such as tinnitus, hearing loss, nausea, GI distress, occult bleeding, dyspepsia, GI bleeding, leukopenia, hepatitis, rash, urticaria and others.
Instructed in new medication Atenolol to manage hypertension. In addition, warned of possible S/E such as fatigue, lethargy, vertigo, drowsiness, dizziness, fever, bradycardia, hypotension, heart failure, intermittent claudication, nausea, diarrhea, thrombocytopenia, hyperkalemia, hypoglycemia, increased risk of developing type-two diabetes, dyspnea, bronchospasm, rash and leg pain. Instructed to take drug exactly as prescribed at the same time every day. Do not stop drug suddenly but do call prescriber if unpleasant adverse reactions occur. If pulse rate is below 60 beats/minute, stop taking drug and call prescriber. Women: notify prescriber if pregnancy occurs. Drug usage might be discontinued.
Instructed in new medication Atorvastatin to reduce cholesterol levels. In addition, warned of possible S/E such as headache, asthenia, insomnia, peripheral edema, rhinitis, pharyngitis, sinusitis, abdominal pain, dyspepsia, flatulence, nausea, constipation, diarrhea, urinary tract infection, arthritis, arthralgia, myalgia, bronchitis, rash, infection, flu-like syndrome, and allergic reaction.
Atorvastatin is contraindicated during pregnancy because of potential danger to the fetus. To notify prescriber immediately if pregnancy occurs or is suspected.
Instructed in new medication Synthroid and in S/E such as nervousness, insomnia, tremor, headache, fever, tachycardia, palpitations, arrhythmias, angina pectoris, cardiac arrest, diarrhea, vomiting, menstrual irregularities, weight loss, allergic skin reactions, diaphoresis or heat intolerance.
Instructed in new medication Metaproterenol sulfate, to manage bronchial asthma. In addition, warned of possible S/E such as vertigo, headache, nervousness, dry and irritated throat, vomiting, nausea, dry mouth, etc.
Instructed in vitamin B12, ordered to management anemia and in S/E such as itching, urticaria, pain or burning in injection sites, transient diarrhea, transitory exanthema, etc.
Instructed in Vitamin B1 and in S/E such as weakness, restlessness, nauseas, uriticaria, pruritus, tenderness, and ?induration after IM administration. .
